Vertiva (automatic drug injection device)

2023: System Release

In June 2023, the company Stevanato launched a new drug delivery system called Vertiva. The platform is capable of switching between basal and bolus injections, and is also suitable for a wide range of subcutaneous therapies, the manufacturer claims.

In March 2023, Stevanato announced plans to bring this body device to market through a collaboration with Thermo Fisher Scientific. Stevanato plans to offer a platform in the form of an integrated device and solution for filling and completing work.

Vertiva Drug Delivery System

Stevanato developed Vertiva as a single-use capsule with a pre-filled and charged 3 ml cartridge. The platform also comes with a reusable controller for potential stability and availability. Both parts of the Vertiva device interact through a magnetically coupled drive mechanism patented by Stevanato.

According to the developers, Vertiva can adapt to different delivery profiles and allows the administration of small molecule drugs and biologics. Stevanato is developing a design for a wide range of volumes up to 10 ml. A preloaded Vertiva cartridge sealed in a capsule during factory assembly allows the patient to take advantage of simplified treatment initiation. They can perform procedures more comfortably at home, and Vertiva's connectivity allows digital medical applications. At the end of treatment, the user can easily separate the capsule from the controller, Stevanato engineers say. In addition, the reusable controller helps reduce the environmental impact of the electronic components of the system.

Vertiva's body delivery system helps pharmaceutical companies increase the availability of home care and physician-supervised treatment options, which could ultimately lead to improved patient conditions! We are excited to bring this device to the market as it further strengthens our integrated drug delivery capabilities, "said Stevanato Vice President of Drug Delivery Systems Steven Kaufman.

With programmable micro-precision basal doses and fully formulated basal injections, Vertiva can cover a range of therapies. These include cardiovascular and metabolic disorders, as well as oncology, immunology and pain relief. Stevanato developed the Vertiva platform, taking into account various individual characteristics of patients, such as greater injection volume, duration of administration and user interface.^[1]

Notes